Vmn1r88 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the Vmn1r88 receptor, a member of the V1R family of vomeronasal receptors. These receptors are primarily involved in the detection of pheromones and play a crucial role in the communication of chemical signals between organisms, particularly in vertebrates. Vmn1r88 is part of the extensive family of G-protein-coupled receptors (GPCRs), which are responsible for various signaling pathways within the body. Inhibitors of this receptor are designed to disrupt the interaction between Vmn1r88 and its associated ligands, preventing the receptor from carrying out its usual signaling functions.
The structural characteristics of Vmn1r88 inhibitors are typically designed to mimic the natural ligands of the receptor, allowing them to bind competitively and block activation. These inhibitors may contain diverse chemical scaffolds, such as heterocyclic structures or aromatic rings, to optimize binding affinity and selectivity for the Vmn1r88 receptor. By inhibiting this receptor, these compounds can modulate the signaling processes associated with pheromone detection, potentially altering the behavior or physiological responses related to Vmn1r88 activation. The study of such inhibitors contributes to a broader understanding of how V1R receptors interact with their ligands and the underlying mechanisms governing olfactory and pheromonal signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic receptor antagonist, potentially modulating GPCR signaling and indirectly affecting Vmn1r88. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Histamine H2 receptor antagonist, may alter GPCR-mediated processes potentially impacting Vmn1r88. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin receptor antagonist, could affect GPCR signaling pathways, influencing Vmn1r88 indirectly. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, potentially affecting noradrenergic signaling related to Vmn1r88. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor antagonist, could modulate GPCR pathways, potentially influencing Vmn1r88 activity. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, may affect calcium signaling pathways, potentially related to Vmn1r88. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Inhibits Gi/o proteins, potentially affecting GPCR-mediated signaling pathways involved with Vmn1r88. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel blocker, might indirectly influence signaling mechanisms relevant to Vmn1r88. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor, could affect downstream signaling pathways that might impact Vmn1r88 function. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Dopamine receptor antagonist, might influence GPCR-mediated signaling pathways related to Vmn1r88. | ||||||